[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100590783":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":52,"collaborators":25,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":25,"eligibilityCriteria":61,"healthyVolunteers":58,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":25,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":25,"overallStatus":75,"whyStopped":25,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Peking University People's Hospital","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"IL-2 group","EXPERIMENTAL","IL-2 group are going to be treated with low-dose IL-2 plus ganciclovir.",[13,14],"Drug: Interleukin-2 (IL-2)","Drug: Ganciclovir (GCV)",{"label":16,"type":6,"description":17,"interventionNames":18},"Control group","Control group will be treated with ganciclovir until negative test for CMV DNA load",[14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Interleukin-2 (IL-2)","Low-dose IL-2 at 1MIU will be administered subcutaneously every other day from baseline to CMV negativity.",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Ganciclovir (GCV)","Ganciclovir injection will be administrated intravenously at a dose of 5mg\u002Fkg per day.",[16,9],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Jing He","CONTACT","818611707347","hejing1105@126.com",[37],{"facility":5,"status":25,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Beijing","Bejing","100044","China","CN",{"type":44,"coordinates":45},"Point",[46,47],116.39723,39.9075,{"lat":47,"lon":46},[50],{"name":32,"role":33,"phone":51,"phoneExt":25,"email":35},"+8618611707347",{"type":53,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","He Jing","PhD, MD","100590783","phase-2-efficacy-and-safety-of-low-dose-il-2-in-sle-patients-with-cmv-viremia-100590783",false,"NCT06971913","Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV Viremia","Inclusion Criteria:\n\n* Meet the American College of Rheumatology criteria for the diagnosis of SLE.\n* The test for plasma CMV DNA viral load is positive.\n* Age: 18 to 65 years, weight 45-80kg, male or female, gender ratio is not limited.\n* Apply corticosteroid less than 1.0mg\u002Fkg\u002Fd.\n* Written informed consent form.\n\nExclusion Criteria:\n\n* Inability to comply with IL-2 treatment regimen;\n* Other active infections. (hepatitis B or C virus, Epstein-Barr virus, human immunodeficiency virus, Mycobacterium tuberculosis or pneumocystis carinii pneumonia)\n* Any anti-CMV vaccine within 6 months;\n* History of intravenous immunoglobulin (IVIG) or leflunomide within 6 months prior to randomization, and those who have undergone plasmapheresis;\n* Active severe neuropsychiatric manifestations of SLE;\n* Severe chronic liver, kidney, lung or heart dysfunction; (heart failure (≥ grade III NYHA), hepatic insufficiency (transaminases\\> 3N));\n* Severe complications. (respiratory failure, heart failure or toxic shock)\n* Complicated with other autoimmune diseases;\n* Cancer or history of cancer cured for less than five years (except in situ carcinoma of the cervix or Basocellular carcinoma);\n* Pregnancy or lactation in females.\n* Mental disorder or any other chronic illness or drug-abuse that could interfere with the ability to comply with the protocol or to give information;\n* Participate in other clinical trial within 3 months.","ALL","18 Years","65 Years",{"count":66,"type":67},100,"ESTIMATED","INTERVENTIONAL",[70],"PHASE2","This clinical trial will assess the efficacy and safety of low-dose interleukin-2 (IL-2) treatment in systemic lupus erythematosus (SLE) complicated with cytomegalovirus (CMV) viremia.",[73,74],"SLE (Systemic Lupus)","CMV","NOT_YET_RECRUITING","2025-05-07",{"date":78,"type":79},"2025-05-14","ACTUAL",{"date":81,"type":67},"2025-05-20",{"date":83,"type":67},"2025-12-30",{"name":5,"class":6},1]